SGFG
PHAT icon

Silver Grove Financial Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Silver Grove Financial Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$879 Buy
+81
New +$924 ﹤0.01% 1891

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Silver Grove Financial Group's PHAT Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Phathom Pharmaceuticals (PHAT) in Q2 2026: 81 shares worth $879. The stake represents ﹤0.01% of the portfolio and ranks #1891 among its holdings.

162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Silver Grove Financial Group held 81 shares of Phathom Pharmaceuticals worth $879 as of Q2 2026.
  • Phathom Pharmaceuticals was a new Silver Grove Financial Group position in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #1891 holding.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.